CERo Therapeutics Receives Notice of Allowance for CER-1236 Patent.

CERo Therapeutics Holdings has received a Notice of Allowance from the US Patent and Trademark Office for Application 19/019,111, granting the company composition of matter protection for CER-1236 and protection for its use in treating cancer, through 2041. This adds to the company's 20 granted patents and allowed applications covering the compound and its underlying technology. The company also obtained a patent in Japan, providing protection for the CER platform.

CERo Therapeutics Holdings, Inc. (NASDAQ: CERO) has received a significant boost to its intellectual property portfolio with a Notice of Allowance from the U.S. Patent and Trademark Office for Application 19/019,111. This patent, set to issue soon, will provide comprehensive protection for CERo's lead compound, CER-1236, and its use in treating cancer through 2041. The patent will cover both the composition of matter and the method of use for CER-1236, strengthening the company's position in the cellular immunotherapy market.

In addition to this U.S. patent, CERo has also secured a patent in Japan for its CER platform. This new patent, along with the 17 other patents and one allowed application already in its portfolio, brings the total number of patents and allowed applications covering CER-1236 and its underlying technology to 20.

The patents granted by the U.S. and Japanese patent offices come at a critical time for CERo, as the company continues to make progress in its Phase 1 clinical trial for CER-1236. The recent FDA Fast Track and Orphan Drug Designations further underscore CERo's strong regulatory position. These developments are expected to provide exclusivity and support the company's efforts to advance its innovative cellular immunotherapy platform.

CERo's CEO, Chris Ehrlich, commented on the significance of the patents, stating, "Our intellectual property portfolio is stronger than ever, with our lead compound now receiving the Notice of Allowance in the United States. Combined with our recent announcements of Fast Track and Orphan Drug Designations from the FDA, we are in a strong regulatory position with regard to exclusivity. We are also continuing to make important progress in our ongoing Phase 1 clinical trial and look forward to continued updates on all developments."

The patents granted to CERo are a testament to the company's innovative approach to T cell engineering, which integrates desirable characteristics of both innate and adaptive immunity into a single therapeutic construct. This unique platform, known as Chimeric Engulfment Receptor T cells (CER-T), is designed to redirect patient-derived T cells to eliminate tumors by employing phagocytic mechanisms.

As CERo continues to advance its clinical trials and expand its intellectual property portfolio, investors and financial professionals should keep an eye on the company's progress. The patents granted and the ongoing clinical trials suggest that CERo is well-positioned to make significant strides in the cellular immunotherapy market.

Reference List:
https://www.stocktitan.net/news/CERO/ce-ro-therapeutics-receives-notice-of-allowance-from-u-s-patent-and-mh7iah6nfa8x.html